GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » EV-to-EBITDA

Transcenta Holding (HKSE:06628) EV-to-EBITDA : -1.31 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Transcenta Holding's enterprise value is HK$629.55 Mil. Transcenta Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-480.29 Mil. Therefore, Transcenta Holding's EV-to-EBITDA for today is -1.31.

The historical rank and industry rank for Transcenta Holding's EV-to-EBITDA or its related term are showing as below:

HKSE:06628' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.59   Med: -1.56   Max: 0.26
Current: -1.31

During the past 5 years, the highest EV-to-EBITDA of Transcenta Holding was 0.26. The lowest was -20.59. And the median was -1.56.

HKSE:06628's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.54 vs HKSE:06628: -1.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Transcenta Holding's stock price is HK$1.76. Transcenta Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.247. Therefore, Transcenta Holding's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Transcenta Holding EV-to-EBITDA Historical Data

The historical data trend for Transcenta Holding's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding EV-to-EBITDA Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -1.54 -2.04 -3.29

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only -1.54 - -2.04 - -3.29

Competitive Comparison of Transcenta Holding's EV-to-EBITDA

For the Biotechnology subindustry, Transcenta Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's EV-to-EBITDA falls into.



Transcenta Holding EV-to-EBITDA Calculation

Transcenta Holding's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=629.551/-480.286
=-1.31

Transcenta Holding's current Enterprise Value is HK$629.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transcenta Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-480.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transcenta Holding  (HKSE:06628) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Transcenta Holding's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.76/-1.247
=At Loss

Transcenta Holding's share price for today is HK$1.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transcenta Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.247.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Transcenta Holding EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding (HKSE:06628) Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines